At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
Levodopa +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Trial to Evaluate Levodopa as Treatment to Improve Vision in Individuals With Albinism
In Brief
A Phase 2 clinical trial evaluating Levodopa and Placebo for Albinism. Completed, enrolled 45 participants across 1 site.
Detailed Summary
This project will evaluate the effect of two doses of levodopa (L-DOPA) in a randomized, placebo-controlled, double-masked clinical trial to see if vision can be improved in individuals with albinism. The hypothesis is that providing L-DOPA to the retinas of these individuals may increase melanin pigment production. Increased melanin has previously been shown to be associated with improved vision.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlbinism
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2010
Enrollment StartSep 2010
Primary CompletionDec 2014
TodayJul 2026
First PostedAug 6, 2010
Enrollment StartSep 1, 2010
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 15.9 years ago
Interventions
Levodopadrug
Solution taken orally three times a day.
Levodopadrug
Solution taken orally three times a day.
Placebodrug
Solution taken orally three times a day.